PLRZ Polyrizon Ltd.
Price Chart
Executive Summary
Polyrizon Ltd. announced the successful production of a GMP-compliant clinical trial material batch for its lead intranasal product candidate, a key milestone enabling its planned U.S. clinical study later this year. This achievement follows prior development batches that confirmed manufacturing consistency and stability.
Actionable Insight
Traders should monitor for upcoming clinical trial initiation and potential regulatory feedback; while this is a procedural milestone, it de-risks development and may precede future catalysts like IND submission or trial data.
Key Facts
- Polyrizon successfully produced a GMP batch of clinical trial material for its lead intranasal product candidate.
- The batch was manufactured in collaboration with Eurofins CDMO AmatsiAquitaine S.A.S.
- Two prior development batches demonstrated batch-to-batch consistency and product stability.
- The GMP material will support upcoming clinical activities and regulatory submissions.
- A U.S. clinical study is planned for later in 2026.
- Polyrizon is a pre-clinical-stage biotech developing nasal spray hydrogels that form a protective barrier against allergens and viruses.
Financial Impact
No direct financial impact disclosed; milestone supports clinical advancement but no revenue or funding figures provided.
Risk Factors
- Clinical trial may not proceed as planned due to regulatory, funding, or operational delays.
- As a pre-clinical company, Polyrizon remains highly speculative with no near-term revenue potential.
- Future financing needs could lead to significant shareholder dilution.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252694 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
10d ago
|
6-K
| $15.18 $13.98 | ▼ −7.91% | ▼ −6.75% | $15.26 (+0.49%) |
|
May 4, 2026
19d ago
|
6-K
| $15.40 $16.12 | ▲ +4.68% | ▲ +1.74% | $15.26 (−0.94%) |
|
Apr 30, 2026
23d ago
|
F-1/A
| — | awaiting T+5 | — | — |
|
Apr 27, 2026
26d ago
|
6-K
| $16.63 $15.40 | ▼ −7.40% | ▼ −7.80% | $15.26 (−8.27%) |
|
Apr 8, 2026
6w ago
|
6-K / PRESS-RELEASE
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $15.26 (−41.91%) |
|
Apr 8, 2026
6w ago
|
424B5
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $15.26 (−41.91%) |
|
Mar 30, 2026
7w ago
|
Insider Cluster
| $11.88 $11.08 | ▲ +6.73% | ▲ +11.03% | $15.26 (−28.41%) |
|
Mar 25, 2026
8w ago
|
Press Release
| $13.75 $12.08 | ▼ −12.15% | ▼ −13.78% | $15.26 (+10.95%) |
|
Mar 24, 2026
8w ago
|
Press Release
| $13.58 $11.68 | ▼ −13.99% | ▼ −13.57% | $15.26 (+12.33%) |
|
Mar 17, 2026
9w ago
|
Press Release
| $13.60 $13.58 | ▼ −0.15% | ▲ +2.51% | $15.26 (+12.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access